Share

Maravai LifeSciences has been granted a patent for methods and compositions to synthesize 5’Capped RNAs using specific initiating capped oligonucleotide primers. The patent covers a method for synthesizing fully templated RNA molecules. GlobalData’s report on Maravai LifeSciences gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData

Report-cover

Premium Insights Maravai LifeSciences Holdings Inc - Company Profile

Buy the Report

Premium Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Maravai LifeSciences, was a key innovation area identified from patents. Maravai LifeSciences's grant share as of February 2024 was 90%. Grant share is based on the ratio of number of grants to total number of patents.

Method for synthesizing 5'capped rnas using specific primers

Source: United States Patent and Trademark Office (USPTO). Credit: Maravai LifeSciences Holdings Inc

A recently granted patent (Publication Number: US11878991B2) discloses a method for synthesizing a fully templated RNA molecule. The method involves introducing an initiating capped oligonucleotide primer with specific structural characteristics. The primer includes various bases such as adenine, N6-methyladenine, guanine, cytosine, or uracil, with specific configurations and combinations outlined in the claims.

Furthermore, the patent details different variations and combinations of the initiating capped oligonucleotide primer, along with the corresponding bases and structural elements involved in the synthesis process. The method aims to provide a precise and controlled approach to synthesizing fully templated RNA molecules, offering potential applications in various fields requiring RNA synthesis with specific characteristics. The claims outline the specific parameters and configurations necessary for the successful implementation of this method, ensuring reproducibility and accuracy in the synthesis process.

To know more about GlobalData’s detailed insights on Maravai LifeSciences, buy the report here.

Premium Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies across the world’s largest industries.